Tuberculosis is the leading cause of death from an infectious disease and is caused by Mycobacterium tuberculosis (MTB). Inosine-5′-monophosphate dehydrogenase (GuaB) is an enzyme that performs the rate-limiting step in the de novo biosynthesis of guanine, which is critical for growth of bacteria, including MTB. The development of a novel antibiotic that inhibits GuaB could …Read More >

Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug, several new strategies have recently become available for targeting the mutant protein. One of the most promising of these involves the use of low molecular weight compounds that promote refolding and reactivation of mutant p53 …Read More >

Frequently observed in NSCLC patients, the 4 amino acid YVMA insertion is the most common type of HER2 exon 20 insertion mutation. A secondary mutation, C805S, often develops as a mechanism of resistance to HER2 tyrosine kinase inhibitors (TKIs) such as poziotinib, where the C805 residue is crucial for drug binding.  The presence of a …Read More >

Psoriasis is a chronic autoimmune skin disease characterized by abnormal keratinocyte proliferation and infiltration of inflammatory cells.  The absence of a suitable animal model that accurately mimics the complex phenotype of psoriasis in humans has hindered the development of promising therapeutics to treat this condition. At SITC 2024, WuXi AppTec presented a poster showcasing the …Read More >

Vitiligo is an autoimmune disorder characterized by the progressive destruction of melanocytes in the skin. This condition is driven by the infiltration of endogenous autoreactive CD8+ T cells, which target and destroy melanocytes, resulting in the clinical manifestation of skin depigmentation. As a common acquired skin disease with no highly effective treatments, there is an …Read More >

Currently, there is a lack of efficient experimental strategies to collect high-quality proteome level data for protein-ligand interactions (PLIs).  At the 2024 ML Drug Discovery Symposium, WuXi AppTec presented a poster showcasing our advanced DELvision database, representing the first use of DNA-encoded library (DEL) technology for establishing a protein-DEL interaction database. The authors demonstrate how …Read More >

Targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. This technology is enabling researchers to pursue targets that were previously considered undruggable and to address the resistance issue of small molecule inhibitors. Since 2016, WuXi AppTec has built a comprehensive TPD discovery …Read More >

Gene therapies are enabling a rapid expansion in the scope of treatable disease.  Adeno-associated viruses (AAVs) are particularly advantageous delivery vehicles for introducing functional genes to specific tissues or cells due to their simplicity, safety, and efficacy. A successful AAV discovery and development pipeline covers basic vector design, in vitro assays, in vivo biodistribution, immunogenicity, …Read More >

Since prostate cancer heavily depends on androgen hormones for growth, targeting the androgen receptor (AR) signaling pathway is a key therapeutic strategy for treating advanced metastatic prostate cancer. While AR antagonists like enzalutamide can significantly improve survival in prostate cancer patients, resistance often develops over time, largely driven by treatment-induced mutations within the ligand-binding domain …Read More >